Berry Jesse L, Xu Liya, Murphree A Linn, Krishnan Subramanian, Stachelek Kevin, Zolfaghari Emily, McGovern Kathleen, Lee Thomas C, Carlsson Anders, Kuhn Peter, Kim Jonathan W, Cobrinik David, Hicks James
The Vision Center at Children's Hospital Los Angeles, Los Angeles, California.
USC Roski Eye Institute, Keck School of Medicine of USC, University of Southern California (USC), Los Angeles.
JAMA Ophthalmol. 2017 Nov 1;135(11):1221-1230. doi: 10.1001/jamaophthalmol.2017.4097.
Retinoblastoma (Rb) is one of the first tumors to have a known genetic etiology. However, because biopsy of this tumor is contraindicated, it has not been possible to define the effects of secondary genetic changes on the disease course.
To investigate whether the aqueous humor (AH) of Rb eyes has sufficient tumor-derived DNA to perform genetic analysis of the tumor, including DNA copy number alterations.
DESIGN, SETTING, AND PARTICIPANTS: This investigation was a case series study at a tertiary care hospital (Children's Hospital Los Angeles) with a large Rb treatment center. Cell-free DNA (cfDNA) was isolated from 6 AH samples from 3 children with Rb, including 2 after primary enucleation and 1 undergoing multiple intravitreous injections of melphalan for vitreous seeding. Samples were taken between December 2014 and September 2015.
Measurable levels of nucleic acids in the AH and identification of tumor-derived DNA copy number variation in the AH. The AH was analyzed for DNA, RNA, and micro-RNA using Qubit high-sensitivity kits. Cell-free DNA was isolated from the AH, and sequencing library protocols were optimized. Shallow whole-genome sequencing was performed on an Illumina platform, followed by genome-wide chromosomal copy number variation profiling to assess the presence of tumor DNA fractions in the AH cfDNA of the 3 patients. One child's cfDNA from the AH and tumor DNA were subjected to Sanger sequencing to isolate the RB1 mutation.
Six AH samples were obtained from 3 Rb eyes in 3 children (2 male and 1 female; diagnosed at ages 7, 20, and 28 months). A corroborative pattern between the chromosomal copy number variation profiles of the AH cfDNA and tumor-derived DNA from the enucleated samples was identified. In addition, a nonsense RB1 mutation (Lys→STOP) from 1 child was also identified from the AH samples obtained during intravitreous injection of melphalan, which matched the tumor sample postsecondary enucleation. Sanger sequencing of the AH cfDNA and tumor DNA with polymerase chain reaction primers targeting RB1 gene c.1075A demonstrated this same RB1 mutation.
In this study evaluating nucleic acids in the AH from Rb eyes undergoing salvage therapy with intravitreous injection of melphalan, the results suggest that the AH can serve as a surrogate tumor biopsy when Rb tumor tissue is not available. This novel method will allow for analyses of tumor-derived DNA in Rb eyes undergoing salvage therapy that have not been enucleated.
视网膜母细胞瘤(Rb)是最早已知有遗传病因的肿瘤之一。然而,由于该肿瘤活检属禁忌,因此无法确定继发基因变化对疾病进程的影响。
研究Rb患者眼房水(AH)中是否含有足够的肿瘤源性DNA,以进行肿瘤的基因分析,包括DNA拷贝数改变。
设计、地点和参与者:本研究是在一家设有大型Rb治疗中心的三级护理医院(洛杉矶儿童医院)开展的病例系列研究。从3例Rb患儿的6份AH样本中分离游离DNA(cfDNA),其中2例为初次眼球摘除术后,1例因玻璃体种植接受多次马法兰玻璃体内注射。样本采集时间为2014年12月至2015年9月。
AH中可测量的核酸水平,以及AH中肿瘤源性DNA拷贝数变异的鉴定。使用Qubit高灵敏度试剂盒对AH进行DNA、RNA和微小RNA分析。从AH中分离cfDNA,并优化测序文库方案。在Illumina平台上进行浅层全基因组测序,随后进行全基因组染色体拷贝数变异分析,以评估3例患者AH cfDNA中肿瘤DNA片段的存在情况。对1例患儿AH中的cfDNA和肿瘤DNA进行Sanger测序,以分离RB1突变。
从3例患儿(2例男性和1例女性;诊断时年龄分别为7、20和28个月)的3只Rb眼中获得6份AH样本。在AH cfDNA的染色体拷贝数变异图谱与眼球摘除样本的肿瘤源性DNA之间发现了相互印证的模式。此外,在马法兰玻璃体内注射期间获得的AH样本中,还从1例患儿中鉴定出一个无义RB1突变(Lys→STOP),与二次眼球摘除后的肿瘤样本相符。使用靶向RB1基因c.1075A的聚合酶链反应引物对AH cfDNA和肿瘤DNA进行Sanger测序,证实了相同的RB1突变。
本研究评估了接受马法兰玻璃体内注射挽救治疗的Rb患者AH中的核酸,结果表明,当无法获得Rb肿瘤组织时,AH可作为替代肿瘤活检。这种新方法将允许对未进行眼球摘除的接受挽救治疗的Rb患者眼中的肿瘤源性DNA进行分析。